$The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio: Myeloma$

The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio: Myeloma

The aim of this study was the evaluation of the effect of intermediate doses of thalidomide with dexamethasone (Thal/Dex) on disease course and bone disease in patients with refractory/relapsed myeloma who were under zoledronic acid therapy. We studied 35 patients, who received thalidomide at a dose...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2005-11, Vol.19 (11), p.1969-1976
Hauptverfasser:	Terpos, E, Mihou, D, Szydlo, R, Tsimirika, K, Karkantaris, C, Politou, M, Voskaridou, E, Rahemtulla, A, Dimopoulos, M A, Zervas, K
Format:	Artikel
Sprache:	eng
Schlagworte:	Cancer Research Critical Care Medicine Hematology Intensive Internal Medicine Medicine Medicine & Public Health Oncology original-manuscript
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!